In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GemVax AS

Division of GemVax & KAEL
www.gemvax.com

Latest From GemVax AS

Clavis Pharma AS

Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • GemVax & KAEL
  • Senior Management
  • Mona Moller, PhD, CEO
  • Contact Info
  • GemVax AS
    Phone: (47) 35 57 41 07
    Teknologisenteret
    Kjolnes Ring
    Porsgrunn, NO-3918
    Norway
Advertisement
Advertisement
UsernamePublicRestriction

Register